Sanofi stands up for diabetes therapy in crowded GLP-1 contest

By Ryan McBride Sanofi ($SNY) is making a case for why its experimental diabetes drug Lyxumia stands out from existing GLP-1 therapies, as the French drug giant eyes the new med to ...

Takeda builds up new vaccine unit with $60M LigoCyte buyout

By Ryan McBride Takeda has snapped up LigoCyte Pharmaceuticals and the venture-backed biotech’s lead vaccine candidate against a notorious foodborne stomach bug called norovirus ...

Big Pharma to benefit from growth in diabetes: S&P

Some bad news on diabetes may be good news for global drug makers. Companies with strong diabetes-treatment portfolios are in for some profitable times over the next few years as an ...

This Big Pharma Pair Parts Ways

By Brian Orelli Bristol-Myers Squibb (NYSE: BMY  ) andSanofi (NYSE: SNY  ) have been through a lot together, making tens of billions of dollars from selling Plavix, Avapro, ...

New Indication for Abbott’s Humira

By Zacks Equity Research Abbott Labs (ABT) recently announced that it has received approval for an additional indication of Humira (adalimumab) from the US Food and Drug Administration ...

J&J’s $74 Value Hinges On Medical Devices Growth And Pharma Pipeline

Johnson & Johnson recently reported its Q2 results, which were mostly in-line with our expectations. To see our full analysis of JNJ’s Q2 earnings, refer to our note Johnson ...

3 Biotech Stocks That Will Be Making Big Moves

By Brian Stoffel Let’s get one thing clear: The stocks I’m about to talk about are not for the faint of heart. Over the coming months and years, the three companies I’m ...

Is Wall Street Turning on Amarin?

By Dave Williamson Today, Fool.com health-care analysts Brenton Flynn and David Williamson look at an unexpected downgrade of Amarin from Wedbush Securities. While Wedbush still ...

Novo Says It’s Likely to Benefit From Bristol-Amylin Tie-Up

By Albertina Torsoli Novo Nordisk A/S (NOVOB) predicts it will benefit from Bristol-Myers Squibb Co. (BMY)’s $5.3 billion purchase of Amylin Pharmaceuticals Inc. as their promotion ...

Roche Faces New Foe as Boehringer Plans a Rituxan Copy

By Naomi Kresge Boehringer Ingelheim GmbH is planning to test a version of Roche Holding AG (ROG)’s top-selling drug Rituxan with a trial design that may speed the copy to market. Boehringer ...

FTC Asks Supreme Court To Review Pay To Delay

By Ed Silverman The US Supreme Court is being asked to review yet another so-called ‘pay-to-delay’ case. The latest request has been made by the US Solicitor General – at the ...

Study: Women fare worse with stents than men

By Damian Garde Women implanted with stents face higher rates of in-hospital death and vascular complications than their male counterparts, according to a study, highlighting concerns ...
Page 2 of 10512345...102030...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS